Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (1): 6-10.doi: 10.6040/j.issn.1671-7554.0.2018.1331

Previous Articles    

Focal cryoablation for prostate cancer

ZHOU Fangjian1, HUANG Hua2, LI Yonghong1   

  1. 1. Department of Urology, Cancer Center of Sun Yat-Sen University, Guangzhou 510060, Guangdong, China;
    2. Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510089, Guangdong, China
  • Published:2022-09-27

PDF (PC)

3

Abstract: In recent years, advances in pathology, imaging, targeted biopsy and cryoablation techniques have promoted the development of focal cryoablation in the treatment of prostate cancer. Focal cryoablation targets on the index lesion and surrounding tissues. Multiparametric MRI(mpMRI)and prostate biopsy are performed to confirm the index lesion before focal cryoablation. Prostate specific antigen(PSA), mpMRI and prostate biopsy are regularly reviewed after focal 山 东 大 学 学 报 (医 学 版)57卷1期 -周芳坚,等.前列腺癌的局灶冷冻治疗 \=-therapy. Compared with whole gland therapy, focal cryoablation has comparable biochemical recurrence-free survival, but better preservation of urinary continence and sexual function. However, further clinical trials are needed for patient selection, operating techniques, assessment of outcome assessment, follow-up modalities and long-term efficacy.

Key words: Prostate cancer, Focal therapy, Cryoablation, Index lesion, Multiparametric MRI, Targeted biopsy

CLC Number: 

  • R737.25
[1] Langenhuijsen JF, Broers EM, Vergunst H. Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology[J]. Eur Urol, 2009, 55(1): 76-86.
[2] Cohen JK, Miller RJ Jr, Ahmed S, et al. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy[J]. Urology, 2008, 71(3): 515-518.
[3] Babaian RJ, Donnelly B, Bahn D, et a1. Best practice statement on cryosurgery for the treatment of localized prostate cancer[J]. J Urol, 2008, 180(5): 1993-2004.
[4] Edison E, Tariq Shah T, Ahmed HU. Focal Ablation of Early Stage Prostate Cancer Candidate Selection, Treatment Guidance, and Assessment of Outcome[J]. Urol Clin North Am, 2017, 44(4): 575-585.
[5] Bahn DK, Silverman P, Lee F Sr, et al. Focal Prostate Cryoablation: Initial Results Show Cancer Control and Potency Preservation[J]. J Endourol, 2006, 20(9): 688-692.
[6] Eisenberg ML, Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure[J]. Urology, 2008, 72(6): 1315-1318.
[7] 董柏君, 王艳青, 谢少伟, 等. 靶向冷冻消融治疗局限性前列腺癌的临床研究[J]. 中华泌尿外科杂志, 2016, 37(10): 754-757. DONG Bojun, WANG Yanqing, XIE Shaowei, et al. Targeted cryoablation for treating localized prostate cancer[J]. Chinese Journal of Urology, 2016, 37(10): 754-757.
[8] Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013[J]. Eur Urol, 2014, 65(1): 124-137.
[9] Ahmed HU, Akin O, Coleman JA, et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer[J]. BJU Int, 2012, 109(11): 1636-1647.
[10] Cordeiro ER, Cathelineau X, Thüroff S, et al. High-intensity focused ultrasound(HIFU)for definitive treatment of prostate cancer[J]. BJU Int, 2012, 110(9): 1228-1242.
[11] Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable(stage T1c)prostate cancer[J]. JAMA, 1994, 271(5): 368-374.
[12] Nevoux P, Ouzzane A, Ahmed HU, et al. Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series[J]. BJU Int, 2012, 110(4): 517-523.
[13] Ahmed HU. The index lesion and the origin of prostate cancer[J]. N Engl J Med, 2009, 361(17): 1704-1706.
[14] Diolombi ML, Epstein JI. Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy[J]. BJU Int, 2017, 119(6): 872-878.
[15] Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy[J]. J Urol, 2011, 185(3): 869-875.
[16] Ahmed HU, Arya M, Freeman A, et al. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?[J]. Lancet Oncol, 2012, 13(11): e509-e517.
[17] Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings[J]. J Urol, 2006, 176(6 Pt 1): 2432-2437.
[18] Choy B, Pearce SM, Anderson BB, et al. Prognostic significance of percentage and architectural types of contemporary Gleason pattern 4 prostate cancer in radical prostatectomy[J]. Am J Surg Pathol, 2016, 40(10): 1400-1406.
[19] Shah TT, Kasivisvanathan V, Jameson C, et al. Histological outcomes after focal high-intensity focused ultrasound and cryotherapy[J]. World J Urol, 2015, 33(7): 955-964.
[20] Valerio M, Cerantola Y, Eggener SE, et al. New and established technology in focal ablation of the prostate: a systematic review[J]. Eur Urol, 2017, 71(1): 17-34.
[21] Ritch CR, Katz AE. Update on cryotherapy for localized prostate cancer[J]. Curr Urol Rep, 2009, 10(3): 206-211.
[22] Ganzer R, Arthanareeswaran VKA, Ahmed HU, et al. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology(ESUT)position statement[J]. Prostate Cancer Prostatic Dis, 2018, 21(2): 175-186.
[23] Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management[J]. J Clin Oncol, 2009, 27(26): 4321-4326.
[24] Nogueira L, Wang L, Fine SW, et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI[J]. Urology, 2010, 75(2): 472-477.
[25] Elshafei A, Tay KJ, Kara O, et al. Associations between prostate volume and oncologic outcomes in men undergoing focal cryoablation of the prostate[J]. Clin Genitourin Cancer, 2018, 16(2): e477-e482.
[26] Valerio M, Shah TT, Shah P, et al. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study[J]. Urol Oncol, 2017, 35(4):150.e1-150150.e7.
[27] Mathew MS, Oto A. MRI-guided focal therapy of prostate cancer[J]. Future Oncol, 2017, 13(6): 537-549.
[28] Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database(COLD)Registry[J]. BJU Int, 2012, 109(11): 648-1654.
[29] Li YH, Elshafei A, Agarwal G, et al. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry[J]. Prostate, 2015, 75(1):1-7.
[30] Muller BG, van den Bos W, Brausi M, et al. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project[J]. World J Urol, 2015, 33(10): 1503-1509.
[1] XU Zhen, DIAO Tongxiang, ZANG Zhenjie, SHAO Dingchang, ZHANG Qi, SUN Dingqi, FU Qiang. Value of isoform［-2］proprostate-specific antigen and its derivatives in the diagnosis of prostate cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 51-56.
[2] SUN Haoyu, JIANG Xin, CHEN Shouzhen, QU Sifeng, SHI Benkang. Multiparametric magnetic resonance imaging combined with prostate health index in the diagnosis of prostate cancer in 142 patients within PSA grey zone [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 46-50.
[3] Benkang SHI,Shouzhen CHEN,Sifeng QU,Yong WANG,Lei LIU. Research progress and clinical characteristics of clinical rapidly progressing prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 110-116.
[4] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[5] SUN Dingqi, FU Qiang, ZHANG Hui, LIU Shuai, DIAO Tongxiang, CAO Qingwei, ZHANG Keqin. Clinical value of targeted multiparameter MRI and transrectal ultrasonography fusion prostate biopsy for the detection of PI-RADS≥3 prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 108-113.
[6] LÜ Jiaju, HU Jialin, DING Sentai. Advances in focal therapy for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 1-5.
[7] MAO Shaowei, LU Guoliang, LI Liang, XIA Qinghua. Valproic acid augments the anti-tumor potential of metformin in PC-3 cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 48-53.
[8] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[9] ZHAI Hongyun, ZHANG Denglu, WANG Guangjie, KONG Feng, CHENG Guanghui, ZHAO Shengtian. Effects of factors secreted by mouse embryonic stem cells on prostate cancer cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 8-12.
[10] DING Huan1, SUN Ying1, LI Xiao-qing2, LI Li1. Effect of PARP inhibitor combined with Gemcitabine or Docetaxel on the  proliferation of androgen-independent prostate cancer cell line PC3 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 33-36.
[11] ZHENG Yi, JIANG Wei, JIN Xun-bo, WANG Mu-wen, ZHANG Yi-nan, XIA Qing-hua. Valproic acid induces autophagy and regulates the expression of  SPARCL1 protein in prostate cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 32-35.
[12] GAO Feng-bin, SI Man-fei, LIU Yong-qing, NIU Lei-lei, YUAN Hui-qing. Retigeric acid B induced cell cycle arrest in human prostate cancer cells by upregulation of p21CIP1 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(12): 34-40.
[13] LI Xian-zhe1, SI Man-fei1,2, GUO Yan-xia1, YUAN Hui-qing1 . Differential expression and regulation of PDLIM4 in prostate cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(06): 34-39.
[14] YU Zhang-jian1, ZHANG Shi-bao1, LIU Qing-yong1, RUAN Xi-yun2, YANG Guang-xiao3, WANG Quan-ying3. Construction of a recombinant adenoassociated viral vector expressing SAC and its inhibition on CAM xenograft prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 41-.
[15] CHEN Weiguo1, LONG Huimin2, HOU Jianquan1, PU Jinxian1, YAN Chun yin1. Inhibitory effect of Gefitinib on hormone independent prostate cancer in vitro and in vivo [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(1): 52-55.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd